Instruction for use: Biperiden (Biperidenum)

Chemical name

Α- (Bicyclo [2.2.1] hept-5-en-2-yl) -alpha- phenyl-1-piperidinepropanol (as hydrochloride or lactate)

Pharmacological group

M-, n-anticholinergics

Nosological classification (ICD-10)

G20 Parkinson's disease

Tremor paralysis, Idiopathic Parkinsonism, Parkinson's disease, Symptomatic Parkinsonism

G21 Secondary parkinsonism

Parkinson's Drug, Parkinsonism, symptomatic Parkinsonism, The lesions of the extrapyramidal system, Parkinson's syndrome

G25 Other extrapyramidal and motor disorders

Extrapyramidal disorders, Disorders of extrapyramidal system, Cerebellar movement disorders, Extrapyramidal hyperkinesis, Pyramidal spastic paresis, The defeat of the pyramidal system, The defeat of the extrapyramidal system

Y49.3 Adverse reactions in the therapeutic use of antipsychotic and neuroleptic drugs phenothiazine series

Y49.4 Adverse reactions in the therapeutic use of neuroleptics-derivatives of butyrophenone and thioxanthene

Y49.5 Adverse reactions in the therapeutic use of other antipsychotic and antipsychotics

Y88.0 Consequences of adverse effects of medicinal products, medicines and biological substances used for therapeutic purposes

Amenorrheadue to prolonged courses of antibiotic therapy

Code CAS 514-65-8

Characteristics

White crystalline powder, odorless, slightly soluble in water and alcohol.

Pharmacology

The pharmacological action is antiparkinsonian.

It blocks central n-cholinergic receptors and peripheral m-cholinergic excitation transfer; The latter provides miotropic and spasmolytic effects.

Cmax (1.01-6.53 ng / ml) is achieved after 0.5-2 h, the equilibrium concentration at ingestion of 2 mg 2 times / day - after 15.7-40.7 hours. It binds to plasma proteins at 91 -94%. The clearance in plasma is 11.6 ml / min / kg. Completely metabolized. The main metabolites are bicycloheptane and piperidine. Elimination is carried out in two phases with T1 / 2 1.5 hours in the first phase and 24 hours in the second phase. Excreted by the kidneys and the digestive tract. Bioavailability when introduced into the digestive tract is 33%. Penetrates into breast milk.

Reduces muscle rigidity, tremors and vegetative disorders, to a lesser extent - the symptoms of akinesia.

Indications

Parkinsonism syndrome, Parkinson's disease, extrapyramidal disorders, dyskinesias, drug induced akinesia, incl. Neuroleptics.

Contraindications

Hypersensitivity, zakratougolnaya glaucoma, megacolon, gastrointestinal obstruction, tachyarrhythmia, prostatic hypertrophy, pregnancy, breastfeeding.

pregnancy and lactation

The action category for fetus by FDA is C.

Side effects of Biperiden

From the nervous system and sensory organs: increased fatigue, weakness, dizziness, drowsiness, anxiety, confusion, euphoria, memory impairment, hallucinations, mydriasis, disruption of accommodation.

From the cardiovascular system and blood (hematopoiesis, hemostasis): tachycardia / bradycardia, lowering blood pressure.

On the part of the intestine: dry mouth, dyspeptic disorders.

Other: allergic reactions, difficulty urinating, drug dependence.

Interaction

Strengthens the effects of anticholinergics, antihistamines, anti-Parkinsonian and anticonvulsants, weakens - metoclopramide. Incompatible with alcohol. Quinidine increases cholinolytic effect, levodopa - the risk of dyskinesia.

Overdose

Symptoms: pronounced cholinolytic effects.

Treatment: symptomatic. Possible use of cholinesterase inhibitors.

Routes of administration

Inside, in / in, / m.

Precautions for the substance Biperiden

Caution is prescribed for atherosclerosis of cerebral vessels (elderly), patients with epilepsy (should consider the possibility of developing convulsive syndrome). Stop treatment gradually (the probability of occurrence of abstinence is high). Patients taking the drug should refrain from engaging in potentially dangerous activities that require rapid mental and motor reactions.